| scholarly article | Q13442814 |
| P2093 | author name string | Ming Tan | |
| Xi Jiang | |||
| P2860 | cites work | From the circumsporozoite protein to the RTS, S/AS candidate vaccine | Q37608882 |
| Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design | Q37792984 | ||
| Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development | Q38059059 | ||
| Virus-like particle-based human vaccines: quality assessment based on structural and functional properties | Q38152530 | ||
| Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines | Q38998392 | ||
| Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. | Q39272520 | ||
| Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine | Q39681193 | ||
| Laboratory efforts to cultivate noroviruses | Q40600126 | ||
| A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice | Q40925262 | ||
| Elicitation of HIV-1 neutralizing antibodies by presentation of 4E10 and 10E8 epitopes on Norovirus P particles | Q41235708 | ||
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
| Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry | Q46851930 | ||
| The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection | Q49105055 | ||
| A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. | Q51525883 | ||
| Human hepatitis B vaccine from recombinant yeast | Q52850114 | ||
| First HEV vaccine approved | Q56656389 | ||
| Norovirus P Particle as a Platform for Antigen Presentation | Q57535514 | ||
| The formation of P particle increased immunogenicity of norovirus P protein | Q83274630 | ||
| A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity | Q28257857 | ||
| A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants | Q28278852 | ||
| Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites | Q28541281 | ||
| Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. | Q30375991 | ||
| A vaccine against nicotine for smoking cessation: a randomized controlled trial | Q33346321 | ||
| Subviral particle as vaccine and vaccine platform | Q33812653 | ||
| A universal influenza A vaccine based on the extracellular domain of the M2 protein | Q33875466 | ||
| Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial | Q34043843 | ||
| Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection | Q34054427 | ||
| Branched-linear and agglomerate protein polymers as vaccine platforms | Q34064413 | ||
| The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors | Q34123964 | ||
| Generation of a parvovirus B19 vaccine candidate | Q34355555 | ||
| Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | Q34415030 | ||
| Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody Production | Q34485266 | ||
| Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles | Q34724844 | ||
| Success and failure of vaccines against renin-angiotensin system components | Q34999478 | ||
| Safety and immunogenicity of a candidate parvovirus B19 vaccine | Q35268947 | ||
| A candidate dual vaccine against influenza and noroviruses | Q35301295 | ||
| Characterization and replicase activity of double-layered and single-layered rotavirus-like particles expressed from baculovirus recombinants | Q35859754 | ||
| The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan | Q35986983 | ||
| Noroviral P particle: structure, function and applications in virus-host interaction | Q36429481 | ||
| Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus | Q36445296 | ||
| A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus | Q36519453 | ||
| Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein | Q36685153 | ||
| Polyvalent complexes for vaccine development | Q36792270 | ||
| Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus | Q36914794 | ||
| Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B. | Q36970026 | ||
| Norovirus vaccine against experimental human Norwalk Virus illness | Q37144052 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| A dual vaccine candidate against norovirus and hepatitis E virus | Q37502688 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 180-185 | |
| P577 | publication date | 2016-09-20 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Recent advancements in combination subunit vaccine development | |
| P478 | volume | 13 |
| Q59359191 | A flagellin-adjuvanted PED subunit vaccine improved protective efficiency against PEDV variant challenge in pigs |
| Q91576751 | Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine Platform |
| Q90484342 | Bioengineered Polyhydroxyalkanoates as Immobilized Enzyme Scaffolds for Industrial Applications |
| Q53056444 | Genome-wide identification of novel vaccine candidates for Plasmodium falciparum malaria using integrative bioinformatics approaches. |
| Q92881172 | Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms |
| Q30234848 | Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy |
| Q92421529 | Immunogenicity and Efficacy Evaluation of Subunit Astrovirus Vaccines |
| Q57063936 | Immunogenicity and Protective Activity of a Chimeric Protein Based on the Domain III of the Tick-Borne Encephalitis Virus E Protein and the OmpF Porin of Incorporated into the TI-Complex |
| Q90231715 | Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development |
| Q49924128 | PED subunit vaccine based on COE domain replacement of flagellin domain D3 improved specific humoral and mucosal immunity in mice |
Search more.